[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hpv-dna\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hpv-dna":35},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,65],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":38,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":64},"100614592","evaluation-of-the-q-pad-hrhpv-test-system-for-identifying-precancer-100614592",false,"NCT07281599","Evaluation of the Q-Pad hrHPV Test System for Identifying Precancer","EQUIP","Inclusion Criteria:\n\n* You are 25 years old or older and have an intact cervix.\n* You were referred for a colposcopy after an abnormal Pap or HPV screen.\n* Your periods come regularly-about every 21-35 days.\n* You own a smartphone, have an email address, and can read the Qvin app instructions in English.\n* You are willing to sign the consent form (electronically).\n* You agree to use a condom for any vaginal intercourse or shared penetrative toy use from Q-Pad collection until the colposcopy visit if engaging with a new sexual partner during this period.\n\nExclusion Criteria:\n\n* You are pregnant or think you might be.\n* You are unwilling or unable to use the two Q-Pads and mail them back (mailing costs are covered).\n* You had treatment for cervical pre-cancer (CIN2+)-such as LEEP, cone, or ablation-within the last 12 months.\n* You have already joined this study or are in another cervical-screening \u002F HPV study right now.",true,"FEMALE","25 Years",{"count":20,"type":21},450,"ESTIMATED","INTERVENTIONAL",[24],"NA","The EQUIP Study is testing whether high-risk human papillomavirus (hrHPV), the virus that causes most cervical cancers, can be accurately detected from menstrual blood collected at home. People who have been referred for colposcopy after an abnormal Pap or hrHPV test will use the Q-Pad Kit during their period to collect menstrual samples on a special menstrual pad and mail them to a central laboratory for hrHPV testing.\n\nThe same participants will have a standard cervical sample collected for routine hrHPV testing and will undergo colposcopy as part of their usual care. By comparing hrHPV results from menstrual samples with results from cervical samples and biopsy findings, the study will evaluate how well the Q-Pad hrHPV Test System detects cervical precancer and will also assess how easy and acceptable it is for participants to use this at-home collection method.",[27,28,29,30,31,32,33,34,35,36,37],"HPV Infection","HPV 16 Infection","High Risk HPV","Cervical Cancer Screening","Cervical Cancer Cin Grade","Cervical Cancer (Early Detection)","HPV","HPV (Human Papillomavirus)-Associated","HPV DNA","HPV Infections","Screening Test",[39,40,41,42,43,44,45,46,47,48,33,49,50,51],"Q-Pad","Self-sampling","Self-collection","self-collect","cervical cancer screening","menstural blood","Sexually Transmitted Diseases, Viral","Sexually Transmitted Diseases","Genital Diseases","Papillomavirus Infections","high risk HPV","pap smear","at-home collection","RECRUITING","2026-01-29",{"date":55,"type":56},"2026-02-02","ACTUAL",{"date":58,"type":56},"2025-12-01",{"date":60,"type":21},"2027-03",{"name":62,"class":63},"Qurasense","INDUSTRY",4,{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":72,"enrollmentInfo":73,"targetDuration":4,"studyType":22,"phases":75,"briefSummary":76,"conditions":77,"keywords":79,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":90,"leadSponsor":92,"locationsCount":95},"100596843","accelerating-adoption-of-patient-centered-cervical-cancer-screening-and-treatment-linkage-in-kenya-100596843","NCT07050745","Accelerating Adoption of Patient-centered Cervical Cancer Screening and Treatment Linkage in Kenya","DADA-LINK","Inclusion Criteria:\n\n\\- Women ages 25-49 years\n\nExclusion Criteria:\n\n* Pregnant women\n* Women ≤6 weeks postpartum\n* Women already confirmed to have cervical cancer","49 Years",{"count":74,"type":21},1980,[24],"This study aims to test the use of a multi-component care strategy (DADA LINK) designed to improve cervical cancer screening and linkage to treatment. The duration of the trial is 12 months, with a 6-month follow-up period to evaluate intervention costs and measure maintenance of the care strategies. Study staff at each clinic will abstract data on cervical cancer screening and triage\u002Ftreatment. Clinics randomized to the intervention arm will have care coordinators who motivate clinic staff to adhere to cervical cancer care guidelines, conduct patient exit surveys to assess intervention fidelity, and support care coordination through use of the mHealth platform (WEMA).",[78,30,35],"Cervical Cancer",[80,81,82,83,84,33,85],"cervical cancer","screening","m-Health","linkage to treatment","VIA","HPV self-sampling","2026-01-08",{"date":88,"type":56},"2026-01-12",{"date":58,"type":56},{"date":91,"type":21},"2026-12",{"name":93,"class":94},"Kenyatta National Hospital","OTHER_GOV",1]